Patents by Inventor Sofia Karlstrom
Sofia Karlstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8158785Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: September 27, 2007Date of Patent: April 17, 2012Assignee: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20110319426Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: September 6, 2011Publication date: December 29, 2011Applicant: ASTRAZENECA ABInventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
-
Patent number: 8030500Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: GrantFiled: November 13, 2009Date of Patent: October 4, 2011Assignee: AstraZeneca ABInventors: Jörg Holenz, Sofia Karlström, Karin Kolmodin, Johan Lindström, Laszlo Rakos, Didier Rotticci, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg
-
Patent number: 7960395Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: GrantFiled: September 27, 2007Date of Patent: June 14, 2011Assignee: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlström, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20110105537Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: January 19, 2011Publication date: May 5, 2011Applicant: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlström, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20100125087Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: AstraZeneca ABInventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Laszlo RAKOS, Peter SODERMAN, Britt-Marie SWAHN, Stefan VON BERG, Fredrik VON KIESERITZKY
-
Publication number: 20100125081Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: ASTRAZENECA ABInventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SODERMAN, Marie SUNDSTROM, Britt-Marie SWAHN, Stefan VON BERG
-
Publication number: 20100125082Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: ASTRAZENECA ABInventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
-
Publication number: 20100035899Abstract: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: September 27, 2007Publication date: February 11, 2010Applicant: ASTRAZENECA ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20090233943Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: May 14, 2008Publication date: September 17, 2009Applicants: Astex Therapeutics Limited, AstraZeneca ABInventors: Jeremy Nicholas Burrows, Sven Hellberg, Katharina Hogdin, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Can Slivo
-
Publication number: 20080318981Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.Type: ApplicationFiled: September 27, 2007Publication date: December 25, 2008Applicant: AstraZeneca ABInventors: Rolf Johansson, Sofia Karlstrom, Annika Kers, Gunnar Nordvall, Tobias Rein, Can Slivo
-
Publication number: 20080287460Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: May 14, 2008Publication date: November 20, 2008Applicants: Astex Therapeutics Limited, AstraZeneca ABInventors: Jeremy Nicholas Burrows, Sven Hellberg, Katharina Hogdin, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Can Slivo
-
Publication number: 20080176862Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: December 19, 2007Publication date: July 24, 2008Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITEDInventors: Stefan Berg, Jorg Holenz, Sofia Karlstrom, Jacob Kihlstrom, Johan Lindstrom, Laszlo Rakos
-
Publication number: 20080161269Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: December 19, 2007Publication date: July 3, 2008Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITEDInventors: Stefan Berg, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Jan-Erik Nystrom, Fernando Sehgelmeble, Peter Soderman